Allurion rises after strong weight-loss data from combination therapy

Allurion Technologies

25/11/2025 14:48

** Shares of healthcare firm Allurion Technologies ALUR.N rise 5.3% to $1.18 in early trading

** Says patients using its swallowable gastric balloon followed by low-dose tirzepatide lost an average of 23% of their body weight over 12 months

** Patients also saw lean body mass rise 14%, addressing muscle loss seen with GLP-1 drugs - ALUR

** Says all 76 patients stayed on tirzepatide for full study duration, unlike typical high dropout rates

** Tirzepatide, sold by Eli Lilly as Mounjaro for diabetes and Zepbound for obesity, is a GLP-1 drug that helps control blood sugar and appetite

** Low-dose GLP-1 strategy aims to improve adherence and reduce side effects - ALUR

** Including session's move, stock down ~90 YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))